Elotuzumab

{
  "id": "MLC-T-ONC-002752",
  "term": "Elotuzumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with dexamethasone and either lenalidomide or pomalidomide to treat adults with multiple myeloma. It is used in patients whose cancer was already treated with other anticancer therapies. Elotuzumab binds to a protein called CS1, which is found on myeloma cells and some types of immune cells. Elotuzumab may block CS1 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Empliciti and HuLuc63.",
    "A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells."
  ],
  "synonyms": [
    "Empliciti",
    "HuLuc63"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/elotuzumab/"
}